BridgeBio Pharma, Inc. (BBIO) bonds
Close on Nov 13, 2026Market cap $15.25BP/E –Yield –
Debt
Borrowings on the balance sheet, Sep 30, 2026
BridgeBio Pharma reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2025
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in BridgeBio Pharma's 10-Q for the period ended Sep 30, 2026
| Issue | Coupon | Matures | Amount issued | Carrying value |
|---|---|---|---|---|
| 2027 Notes Initial Purchasers Convertible | – | 2027 | $75.00M | – |
| 2029 Notes Initial Purchasers Convertible | – | 2029 | $67.50M | – |
| 2031 Notes Initial Purchasers Convertible | – | 2031 | $75.00M | – |
| 2033 Notes Initial Purchasers Convertible | – | 2033 | $82.50M | – |
| 2027 Notes, net Convertible at $43 a share | 2.50% | – | $550.00M | $556.88M |
| 2029 Notes, net Convertible at $97 a share | 2.25% | – | $747.50M | $789.55M |
| 2031 Notes, net Convertible at $50 a share | 1.75% | – | $575.00M | $620.28M |
| 2033 Notes, net Convertible at $111 a share | 0.75% | – | $632.50M | $663.35M |
| Term loan, net | – | – | – | $0 |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Drawn |
|---|---|---|
| Financing Agreement | $750.00M | $450.00M |
| Incremental Term Loan | $300.00M | – |
| Initial Term Loan | $450.00M | – |
| Loan Agreement | – | – |
| Loan Agreement | $450.00M | – |
| Tranche One Advance | $450.00M | – |
| Tranche Two Advance | $100.00M | – |
See a number that looks wrong?